Kathy Liu Lab

• Ongoing Projects
• Understanding-and-Targeting-Chromosome-Rearrangement-Induced-Fusion-Oncogenes

Understanding-and-Targeting-Chromosome-Rearrangement-Induced-Fusion-Oncogenes

We are developing highly specific therapies by targeting oncogenic fusion proteins. We have recently developed innovative methodologies to selectively target the oncofusion proteins (US patent 63/797,545). Our commitment to translational research has culminated in the successful development of a targeted therapy for a specific cancer fusion protein, which is currently advancing to clinical trials. This program exemplifies our ability to translate fundamental knowledge of cancer-specific aberrations into tangible clinical benefits for patients. We continue to develop novel strategies to target other clinically relevant cancer fusion proteins, aiming to expand the arsenal of precision medicine approaches in oncology.

Key Highlights:

• Developed innovative methods for targeting cancer fusion proteins.
• Demonstrated success in translating basic research to clinical trials.
• Focus on developing highly specific and potentially less toxic cancer therapies.
• Expanding efforts to identify and target a broader range of clinically relevant fusion proteins.